These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25450346)

  • 1. Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.
    Galatola R; Cruz A; Gómara MJ; Prat J; Alsina MA; Haro I; Pujol M
    Biochim Biophys Acta; 2015 Feb; 1848(2):392-407. PubMed ID: 25450346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models.
    Sánchez-Martín MJ; Busquets MA; Girona V; Haro I; Alsina MA; Pujol M
    Biochim Biophys Acta; 2011 Sep; 1808(9):2178-88. PubMed ID: 21672514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.
    Domènech O; Ortiz A; Pujol M; Haro I; Muñoz M; Alsina MA; Prat J; Busquets MA; Girona V
    Biochim Biophys Acta; 2014 May; 1838(5):1274-80. PubMed ID: 24530897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: interaction with model membranes.
    Sánchez-Martín MJ; Cruz A; Busquets MA; Haro I; Alsina MA; Pujol M
    Int J Pharm; 2012 Oct; 436(1-2):593-601. PubMed ID: 22868231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.
    Sánchez-Martín MJ; Urbán P; Pujol M; Haro I; Alsina MA; Busquets MA
    Chemphyschem; 2011 Oct; 12(15):2816-22. PubMed ID: 21905195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
    Haro I; Gómara MJ; Galatola R; Domènech O; Prat J; Girona V; Busquets MA
    Biochim Biophys Acta; 2011 Jun; 1808(6):1567-73. PubMed ID: 21377446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Langmuir monolayer study of the interaction of E1(145-162) hepatitis G virus peptide with phospholipid membranes.
    Sánchez-Martín MJ; Haro I; Alsina MA; Busquets MA; Pujol M
    J Phys Chem B; 2010 Jan; 114(1):448-56. PubMed ID: 20000622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study in mono and bilayers of the interaction of hepatitis G virus (GBV-C/HGV) synthetic antigen E2(99-118) with cell membrane phospholipids.
    Dastis M; Rojo N; Alsina MA; Haro I; Panda AK; Mestres C
    Biophys Chem; 2004 Jun; 109(3):375-85. PubMed ID: 15110935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
    Galatola R; Vasconcelos A; Pérez Y; Cruz A; Pujol M; Alsina MA; Gómara MJ; Haro I
    Eur J Med Chem; 2014 Oct; 86():589-604. PubMed ID: 25218908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C.
    Sánchez-Martín MJ; Hristova K; Pujol M; Gómara MJ; Haro I; Alsina MA; Busquets MA
    J Colloid Interface Sci; 2011 Aug; 360(1):124-31. PubMed ID: 21565353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis.
    Ziegler A; Blatter XL; Seelig A; Seelig J
    Biochemistry; 2003 Aug; 42(30):9185-94. PubMed ID: 12885253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein.
    Larios C; Casas J; Alsina MA; Mestres C; Gómara MJ; Haro I
    Arch Biochem Biophys; 2005 Oct; 442(2):149-59. PubMed ID: 16165082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysical characterization of the fusogenic region of HCV envelope glycoprotein E1.
    Pérez-Berná AJ; Pabst G; Laggner P; Villalaín J
    Biochim Biophys Acta; 2009 Oct; 1788(10):2183-93. PubMed ID: 19698697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the saturation chain and head group charge of phospholipids in the interaction of hepatitis G virus synthetic peptides.
    Pérez S; Miñones J; Espina M; Alsina MA; Haro I; Mestres C
    J Phys Chem B; 2005 Oct; 109(42):19970-9. PubMed ID: 16853582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational partitioning of the fusion peptide of HIV-1 gp41 and its structural analogs in bilayer membranes.
    Maddox MW; Longo ML
    Biophys J; 2002 Dec; 83(6):3088-96. PubMed ID: 12496080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of lipidated GBV-C/HGV NS3 (513-522) and (505-514) peptides with phospholipids monolayer. An AFM study.
    Weroński KJ; Diez-Pérez I; Busquets MA; López-Iglesias C; Girona V; Prat J
    Colloids Surf B Biointerfaces; 2010 Jan; 75(1):25-33. PubMed ID: 19765957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.
    Herrera E; Gomara MJ; Mazzini S; Ragg E; Haro I
    J Phys Chem B; 2009 May; 113(20):7383-91. PubMed ID: 19402654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of GB virus C/hepatitis G virus synthetic peptides with lipid langmuir monolayers and large unilamellar vesicles.
    Pérez-López S; Vila-Romeu N; Asunción Alsina Esteller M; Espina M; Haro I; Mestres C
    J Phys Chem B; 2009 Jan; 113(1):319-27. PubMed ID: 19195104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage.
    Fernández-Vidal M; Rojo N; Herrera E; Gómara MJ; Haro I
    Biophys Chem; 2008 Jan; 132(1):55-63. PubMed ID: 17988786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The helical propensity of KLA amphipathic peptides enhances their binding to gel-state lipid membranes.
    Arouri A; Dathe M; Blume A
    Biophys Chem; 2013; 180-181():10-21. PubMed ID: 23792704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.